Literature DB >> 24647592

PTEN mutation, loss of heterozygosity, promoter methylation and expression in colorectal carcinoma: two hits on the gene?

Maja Hühns1, Tareq Salem1, Björn Schneider1, Mathias Krohn2, Michael Linnebacher2, Friedrich Prall1.   

Abstract

The phosphatase and tensin homologue (PTEN) gene is considered to be a tumour-suppressor gene in various types of cancer, colorectal carcinoma among them. According to the 'two-hit' tumour-suppressor gene concept, inactivation occurs by any combination of the following three pathogenetic processes: mutation, loss of one allele [i.e. loss of heterozygosity (LOH)] or promoter methylation. To determine the frequencies of PTEN tumour-suppressor gene features in colorectal carcinoma, we used DNA from colorectal carcinoma xenografts/primary tumour cell lines (N=22) or neoplastic glands isolated by laser-capture microdissection (N=20). Sequencing exons 1-9 of the gene revealed a total of 8 somatic mutations in 5 tumours (3 with high-degree microsatellite instability). In 1 tumour, a truncating mutation of one allele was combined with two missense mutations of the other allele. Polymorphic microsatellite marker analyses (D10S5412, D10S579 and D10S1765) showed complete loss of one allele (i.e. LOH sensu stricto) in 3 tumours, but combined LOH and mutation was found only once. Promoter methylation, tested by MethyLight technology, was found in only 1 of the tumours, not combined with mutation or LOH. In contrast, by immunohistochemistry (mAb 6H2.1), reduction or even loss of PTEN expression was found in 18 tumours. Taken together, PTEN downregulation is a fairly frequent event in colorectal carcinoma, but this apparently is not usually caused by two hits on the gene.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24647592     DOI: 10.3892/or.2014.3097

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

Review 1.  Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.

Authors:  Hui Jun Lim; Philip Crowe; Jia-Lin Yang
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-22       Impact factor: 4.553

2.  PREX2 promotes the proliferation, invasion and migration of pancreatic cancer cells by modulating the PI3K signaling pathway.

Authors:  Jianyi Yang; Xuejun Gong; Lu Ouyang; Wen He; Rou Xiao; Li Tan
Journal:  Oncol Lett       Date:  2016-06-08       Impact factor: 2.967

3.  Functional characterization of the nitrogen permease regulator-like-2 candidate tumor suppressor gene in colorectal cancer cell lines.

Authors:  Ai-Yun Liu; Ming-Na Liu; Feng-Hua Pei; Jing Chen; Xin-Hong Wang; Dan Liu; Ya-Ju Du; Bing-Rong Liu
Journal:  Mol Med Rep       Date:  2015-06-03       Impact factor: 2.952

4.  Investigation of PTEN promoter methylation in ameloblastoma.

Authors:  P Lapthanasupkul; B Klongnoi; A Mutirangura; N Kitkumthorn
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2020-07-01

Review 5.  The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities.

Authors:  Hyeyoun Chang; Zhenying Cai; Thomas M Roberts
Journal:  Biomolecules       Date:  2019-11-07

6.  Fluctuations in AKT and PTEN Activity Are Linked by the E3 Ubiquitin Ligase cCBL.

Authors:  Manuel Olazábal-Morán; Miriam Sánchez-Ortega; Laura Martínez-Muñoz; Carmen Hernández; Manuel S Rodríguez; Mario Mellado; Ana C Carrera
Journal:  Cells       Date:  2021-10-20       Impact factor: 6.600

7.  Evaluating the Role of PTEN Promoter Methylation in Patients Predisposed to Hypercoagulable States via Methylation Specific PCR.

Authors:  Majid Hoseini; Mehdi Sahmani; Farshad Foroughi; Yousef Khazaei Monfared; Mehdi Azad
Journal:  Rep Biochem Mol Biol       Date:  2019-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.